<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<REGINFO_RIN_DATA xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" RUN_DATE="2026-04-18-04:00" xsi:noNamespaceSchemaLocation="https://www.reginfo.gov/public/xml/REGINFO_XML_Ver10262011.xsd">
    <RIN_INFO>
        <RIN>3041-AD49</RIN>
        <PUBLICATION>
            <PUBLICATION_ID>202404</PUBLICATION_ID>
            <PUBLICATION_TITLE>Unified Agenda of Federal Regulatory and Deregulatory Actions</PUBLICATION_TITLE>
        </PUBLICATION>
        <AGENCY>
            <CODE>3041</CODE>
            <NAME>Consumer Product Safety Commission</NAME>
            <ACRONYM>CPSC</ACRONYM>
        </AGENCY>
        <RULE_TITLE>Petition for Rulemaking for Various Products Containing Organohalogen Flame Retardants</RULE_TITLE>
        <ABSTRACT><![CDATA[<!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The Commission received a petition requesting that the Commission initiate rulemaking under the Federal Hazardous Substances Act (FHSA) to declare several categories of products containing additive organohalogen flame retardants (OFRs)&nbsp;to be "banned hazardous substances." The Commission requested comments on the petition and heard oral presentations in a public hearing.&nbsp;The Commission voted to grant the petition and directed staff to convene a Chronic Hazard Advisory Panel (CHAP) to assess the risks to consumers&rsquo; health and safety from the use of OFRs, as a class of chemicals, consistent with the FHSA, in the&nbsp;four groups of products. The Commission further directed staff to complete a scoping and feasibility study in cooperation with the National Academy of Sciences (NAS). In July 2020, staff delivered a report to the Commission proposing a plan for collecting and analyzing data to perform risk assessments of specific products containing OFRs. Completed risk assessments, consisting of toxicological hazard assessments and exposure assessments, will provide information for proceeding with the preparation of a proposed rule briefing package for Commission consideration.&nbsp;In 2021, staff initiated multiple tasks under the multi-year plan, and completed a status report to the Executive Director.&nbsp;In fiscal year 2022, staff continued research and data-collection tasks, received completed reports from contractors addressing OFR chemicals markets and uses, and initiated analyses of certain data to support hazard and exposure evaluations of chemicals and chemical classes. In fiscal year 2022, staff continued work with contractors, and the Division of Translational Toxicology of the National Institute of Environmental Health Sciences, U.S. Department of Health and Human Services, on literature searches for toxicity, exposure, and risk data on at least 10 of the 14 OFR identified subclasses and began analyses of OFR metabolism and exposure data. In fiscal years 2023-2024, literature surveys on 12 subclasses, a biomonitoring exposure assessment on a data-rich subclass, and scope documents on all 14 subclasses were completed, as well as all supporting files and reports were posted to the CPSC website. In fiscal year 2024, staff continues work needed to complete toxicity and exposure assessments for OFR subclasses, including completion of a class-based exposure assessment guide, a class-based hazard assessment guide, and literature searches on exposure assessments.</p>
</body>
</html>]]></ABSTRACT>
        <PRIORITY_CATEGORY>Substantive, Nonsignificant</PRIORITY_CATEGORY>
        <RIN_STATUS>Previously Published in The Unified Agenda</RIN_STATUS>
        <RULE_STAGE>Prerule Stage</RULE_STAGE>
        <MAJOR>Undetermined</MAJOR>
        <UNFUNDED_MANDATE_LIST>
            <UNFUNDED_MANDATE>Undetermined</UNFUNDED_MANDATE>
        </UNFUNDED_MANDATE_LIST>
        <CFR_LIST>
            <CFR>Not Yet Determined</CFR>
        </CFR_LIST>
        <LEGAL_AUTHORITY_LIST>
            <LEGAL_AUTHORITY>15 U.S.C. 1262</LEGAL_AUTHORITY>
        </LEGAL_AUTHORITY_LIST>
        <LEGAL_DLINE_LIST/>
        <RPLAN_ENTRY>No</RPLAN_ENTRY>
        <TIMETABLE_LIST>
            <TIMETABLE>
                <TTBL_ACTION>Petition Docketed</TTBL_ACTION>
                <TTBL_DATE>08/05/2015</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Notice for Comment Published in Federal Register</TTBL_ACTION>
                <TTBL_DATE>08/19/2015</TTBL_DATE>
                <FR_CITATION>80 FR 50238</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION> Comment Period End</TTBL_ACTION>
                <TTBL_DATE>10/19/2015</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION> Comment Period Extended</TTBL_ACTION>
                <TTBL_DATE>10/26/2015</TTBL_DATE>
                <FR_CITATION>80 FR 65174</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Public Hearing for Oral Comments</TTBL_ACTION>
                <TTBL_DATE>12/09/2015</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION> Extended Comment Period End</TTBL_ACTION>
                <TTBL_DATE>01/19/2016</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Staff Sends Petition Briefing Package to Commission</TTBL_ACTION>
                <TTBL_DATE>05/24/2017</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Notice of Public Hearing for Oral Comments</TTBL_ACTION>
                <TTBL_DATE>08/07/2017</TTBL_DATE>
                <FR_CITATION>82 FR 36705</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Public Hearing for Oral Comments</TTBL_ACTION>
                <TTBL_DATE>09/14/2017</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Commission Decision</TTBL_ACTION>
                <TTBL_DATE>09/20/2017</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>NAS Completed Feasibility and Scoping Study</TTBL_ACTION>
                <TTBL_DATE>05/03/2019</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Publish Hearing for NAS to Present the Report</TTBL_ACTION>
                <TTBL_DATE>07/24/2019</TTBL_DATE>
                <FR_CITATION>84 FR 34372</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Staff Sends Report to Commission</TTBL_ACTION>
                <TTBL_DATE>07/01/2020</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Data Analysis and/or Technical Review</TTBL_ACTION>
                <TTBL_DATE>09/00/2024</TTBL_DATE>
            </TIMETABLE>
        </TIMETABLE_LIST>
        <RFA_REQUIRED>Undetermined</RFA_REQUIRED>
        <GOVT_LEVEL_LIST>
            <GOVT_LEVEL>None</GOVT_LEVEL>
        </GOVT_LEVEL_LIST>
        <FEDERALISM>Undetermined</FEDERALISM>
        <PRINT_PAPER>No</PRINT_PAPER>
        <INTERNATIONAL_INTEREST>No</INTERNATIONAL_INTEREST>
        <AGENCY_CONTACT_LIST>
            <CONTACT>
                <FIRST_NAME>Charles</FIRST_NAME>
                <LAST_NAME>Bevington</LAST_NAME>
                <TITLE>Project Manager, Directorate for Health Sciences</TITLE>
                <AGENCY>
                    <CODE>3041</CODE>
                </AGENCY>
                <PHONE>301 987-2009</PHONE>
                <EMAIL>cbevington@cpsc.gov</EMAIL>
                <MAILING_ADDRESS>
                    <STREET_ADDRESS>5 Research Place,</STREET_ADDRESS>
                    <CITY>Rockville</CITY>
                    <STATE>MD</STATE>
                    <ZIP>20850</ZIP>
                </MAILING_ADDRESS>
            </CONTACT>
        </AGENCY_CONTACT_LIST>
    </RIN_INFO>
</REGINFO_RIN_DATA>
